Carna Biosciences,Inc. [4572.T]
TOKYO, May 08 (Pulse News Wire) – Carna Biosciences,inc. (4572.T) reported a net loss of ¥529 million for the quarter ending March 2026, compared to a loss of ¥499 million in the same period last year.
Revenue increased by 20%, reaching ¥183 million due to strong sales of proteins domestically and in China, along with robust contract testing services in Europe and North America. The company continued its investment in clinical development programs, particularly focusing on docirbrutinib and monzosertib.
Docirbrutinib's Phase 1b trial showed promising results, with ongoing patient enrollment at various dose levels. Monzosertib’s preparation for physician-led trials also progressed steadily.
In addition, Carna raised funds through the issuance of unsecured convertible bonds and warrants, totaling ¥1.711 billion, aimed at strengthening its financial base and supporting further research and development activities.
🟡 Confidence: Standard AI-translated content.